FREQUENCY OF PULMONARY HYPERTENSION IN CASES OF INTERSTITIAL LUNG DISEASE: CROSS-SECTIONAL STUDY

Z SHAH; . SANAULLAH; S ASLAM; MA KHAN; A BUSHRA

doi:10.54112/bcsrj.v2024i1.1319

Authors

Z SHAH Saidu Group of Teaching Hospital, SWAT, Pakistan
. SANAULLAH Bacha Khan Medical College/Mardan Medical Complex, Mardan, Pakistan
S ASLAM Khyber Teaching Hospital Peshawar, Pakistan
MA KHAN Dr.Ruth K.M PFAU Civil Hospital Karachi, Pakistan
A BUSHRA BHU Padshahan Chakwal, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1319

Keywords:

Pulmonary hypertension, Interstitial lung disease, Prevalence, Smoking, Echocardiography, Risk factors

Abstract

Pulmonary hypertension (PH) is a significant complication of interstitial lung disease (ILD), often contributing to increased morbidity and mortality. Understanding the prevalence and associated risk factors of PH in ILD patients can aid in early detection and tailored management strategies. Objective: .To determine the frequency of pulmonary hypertension in patients with interstitial lung disease. Methods: A cross-sectional study was conducted on 200 patients diagnosed with ILD. Data on demographics, clinical characteristics, smoking history, and comorbidities were collected. Pulmonary hypertension was screened using transthoracic echocardiography, defined as a mean pulmonary artery pressure (mPAP) ≥ 20 mmHg. Statistical analyses were performed to assess associations between PH and patient characteristics. Results: Pulmonary hypertension was observed in 23.5% of the study population. The mean age of participants was 50.63 ± 12.03 years, with a male predominance (56%). Smoking was significantly associated with PH (p = 0.01), with 44.7% of smokers exhibiting PH. Hypertension was common (59.0%) but showed no significant association with PH. No significant differences in PH prevalence were observed based on place of residence or employment status. Conclusion: Pulmonary hypertension is a prevalent complication in ILD, particularly among smokers and males. Routine screening for PH in ILD patients, especially those with known risk factors, is essential for early diagnosis and intervention. These findings emphasize the need for targeted management strategies to mitigate the impact of PH on this vulnerable population.

Downloads

Download data is not yet available.

References

Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. The Lancet. 2022;400(10354):769-86.

Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N, et al. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. The Lancet Respiratory Medicine. 2021;9(9):1065-76.

Faverio P, De Giacomi F, Bonaiti G, Stainer A, Sardella L, Pellegrino G, et al. Management of chronic respiratory failure in interstitial lung diseases: overview and clinical insights. International Journal of Medical Sciences. 2019;16(7):967.

Zubairi ABS, Ansarie M, Mahmud T, Ashraf S, Rao NA, Javaid A, et al. National registry of interstitial lung disease from Pakistan. Cureus. 2021;13(4).

Mandras SA, Mehta HS, Vaidya A, editors. Pulmonary hypertension: a brief guide for clinicians. Mayo Clinic Proceedings; 2020: Elsevier.

Mocumbi AO, Thienemann F, Sliwa K. A global perspective on the epidemiology of pulmonary hypertension. Canadian Journal of Cardiology. 2015;31(4):375-81.

Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1).

Strange G, Stewart S, Celermajer DS, Prior D, Scalia GM, Marwick TH, et al. Threshold of pulmonary hypertension associated with increased mortality. Journal of the American College of Cardiology. 2019;73(21):2660-72.

Waxman AB, Elia D, Adir Y, Humbert M, Harari S. Recent advances in the management of pulmonary hypertension with interstitial lung disease. European Respiratory Review. 2022;31(165).

Young A, Vummidi D, Visovatti S, Homer K, Wilhalme H, White ES, et al. Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis. Arthritis & rheumatology. 2019;71(8):1339-49.

Tyagi R, Kant S, Verma SK, Kushwaha RAS, Kumar S, Garg R, et al. Spectrum of interstitial lung diseases and their association with pulmonary hypertension. Monaldi Archives for Chest Disease. 2022;92(3).

Andersen CU, Mellemkjær S, Hilberg O, Nielsen-Kudsk JE, Simonsen U, Bendstrup E. Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test. Respiratory medicine. 2012;106(6):875-82.

Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. The Journal of rheumatology. 2007;34(5):1005-11.

Alam M, Ansari MIS, Shehzad A, Shehzad MI, Ramzan M, Mushtaq MA. Prevalence of pulmonary hypertension among the patients diagnosed of Interstitial Lung Disease. Pakistan Journal of Chest Medicine. 2023;29(4):287-91.

Arslan A, Smith J, Qureshi MR, Uysal A, Patel KK, Herazo-Maya JD, et al. Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future. Frontiers in Medicine. 2024;10:1306032.